Improved prognosis in disseminated histiocytosis.
Improved prognosis in disseminated histiocytosis.
复制标题
改善播散性组织细胞增多症的预后。
DOI：
--
复制
发表时间：
1976
期刊：
影响因子：
--
通讯作者：
P. Campbell
中科院分区：
文献类型：
--
作者：
P. Smith;H. Ekert;P. Campbell
随着现代化疗原则的应用，以前被认为是糟糕的播散性组织细胞增多症儿童的预后已经显著改善。14例组织细胞增多症患儿的临床分期为：无器官功能障碍者，I期；有器官功能障碍者，II期；组织学类型(B，良性，M，恶性)。他们接受口服氯氨丁苯或联合长春花碱和其他药物的化疗。临床分期对预测治疗反应和预后有价值，而组织学分期价值较小。14名儿童中有13名对治疗有反应，在确诊后存活4至67个月(中位数12个月)。其中两人在治疗过程中复发，他们对治疗方法的改变有了反应。两名儿童在停止治疗后复发，并再次采用类似的治疗方法进行再次诱导。对治疗的初步反应表明，对于最初对治疗有反应但后来复发的儿童，对重新采用相同的治疗或改变治疗的反应是有利的。
The prognosis for children with disseminated histiocytosis, previously considered poor, has improved dramatically with the application of modern principles of chemotherapy. Fourteen children with histiocytosis were staged clinically as follows: those without organ dysfunction, stage I; those with organ dysfunction, stage II; and histologically (B, benign and M, malignant). They were treated with either oral chlorambucil or combination chemotherapy with vinblastine and other agents. Clinical staging was of value in predicting response to treatment and prognosis, while histologic staging was of less value. Thirteen of the 14 children responded to treatment and are alive 4 to 67 months (median 12 months) after diagnosis. Two of these relapsed on treatment, and they have responded to a change in therapy. Two children relapsed after stopping treatment and were reinduced with reintroduction of similar therapy. Initial response to treatment suggests a favourable outcome, for children who initially responded to treatment but relapsed subsequently responded to either reintroduction of the same treatment or a change in treatment.